A Agilent Technologies Inc.

Agilent Presents Thought Leader Award to Professor Chris Elliott

(NYSE: A) today announced that Chris Elliott has received an Agilent Thought Leader Award. Dr. Elliott is Professor of Food Safety in the School of Biological Sciences and founder of the Institute for Global Food Security (IGFS) at in Northern Ireland. The award recognizes his contributions to the field of food authenticity and the development of novel approaches to the detection of food fraud.

This press release features multimedia. View the full release here:

Professor Chris Elliott (Photo: Business Wire)

Professor Chris Elliott (Photo: Business Wire)

is a globally recognized expert on international food supply chains and the implications for food quality, authenticity, integrity, and safety. The award includes an Agilent coupled with a , a instrument, and sample preparation and analysis consumables. The award will support Professor Elliott and his team in developing innovative analytical approaches that will help solve complex food authenticity challenges, focusing on making complex test methods more routine and easier to use.

“I’m deeply honored to be the recipient of such a large and prestigious award,” stated Professor Elliott. “The partnership between our institute and Agilent to provide cutting-edge scientific tools to help combat the growing menace of food fraud globally will go from strength to strength. Together we will help support the development of the global food supply system based on the core principles of integrity.”

“Providing this award to Professor Elliott is an honor as Agilent is committed to helping ensure that the world’s global food supply is safe,” stated Sudharshana Seshadri, vice president of Agilent's Mass Spectrometry Division and executive sponsor of the award. “The development of new test methods that are fast and easier to use will enable much broader adoption and implementation of food authenticity testing in more labs.”

Food fraud is on the rise, impacting a vast array of food products and causing significant concerns for the food industry, regulators, and consumers. Agilent’s advanced mass spectrometry and spectroscopy technologies can effectively analyze food product classification, ascertain contaminant and degradation levels, and help confirm points of origin and production.

The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. To learn more, visit the web site.

About Agilent Technologies

Agilent is a leader in life sciences, diagnostics, and applied chemical markets, delivering innovative technology solutions that provide trusted answers to researchers’ most challenging scientific questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on , , and .

EN
01/06/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch